がん免疫療法創薬アウトソーシングの世界市場レポート 2024年

がん免疫療法創薬アウトソーシング市場規模は、今後数年で急成長が見込まれます。2028年の年間平均成長率（CAGR）は11.4％で、23億1,000万米ドルに成長します。予測期間中に予想される成長は、個別化医療の重要性の高まり、診断試験の利用可能性の増加、個別化がん治療への注目の高まり、医療支出の増加、がん罹患に対する意識の高まりなど、いくつかの要因に起因しています。予測期間中に予想される主要動向には、診断技術の進歩、次世代シーケンシング（NGS）の採用、人工知能（AI）の統合、リキッドバイオプシー技術の進歩、ポイントオブケア型コンパニオン診断機器の開発、革新的な試験技術などが含まれます。

研究開発（R&D）に関連する経費の高騰が、がん免疫療法創薬アウトソーシング市場の拡大を牽引すると予測されます。多額の研究開発費は、専門的な知識、高価な機器、技術革新に伴う固有のリスクの必要性から生じています。創薬活動のアウトソーシングは、開発業務受託機関（CRO）が提供するスケールメリットを活用することで、小規模なバイオテクノロジー企業や新興企業が研究開発予算を最適化し、リソースをより効率的に配分することを可能にし、費用対効果を高める。例えば、2023年6月に欧州製薬団体連合会（EFPIA）が報告したところによると、2022年の欧州の医薬品研究開発費総額は495億米ドル（445億ユーロ）に達し、2021年の465億米ドル（425億3,300万ユーロ）から約6.45％増加しました。その結果、自社研究開発に関連する法外なコストががん免疫療法創薬アウトソーシング市場の成長に拍車をかけています。

がん免疫療法創薬アウトソーシング市場の主要参入企業は、抗がん剤生産を強化し、競合優位性を獲得するために、戦略的パートナーシップのアプローチを採用しています。戦略的パートナーシップは通常、2つ以上の組織が協力関係を結び、共通の目標や目的を達成するためにリソースや専門知識、努力を出し合うことを意味します。例えば、2022年2月、日本の製薬会社である小野薬品工業株式会社と米国のバイオ医薬品会社であるBristol-Myers Squibbは、日本の研究機関であるPrime Research Institute for Medical Research, Inc.と、オプジーボ（ニボルマブ）と化学療法を併用した胃がん患者に焦点を当てた共同臨床研究プロジェクトに関する業務委託契約を締結しました。この共同研究は、Prime Research Institute for Medical Research, Inc.のCyberOncologyデータ入力支援システムを用いた大規模な多施設共同研究であり、日常的ながん臨床における実臨床データの標準化、構造化、管理、統合を促進するものです。CyberOncologyを活用した臨床研究では、未治療の進行・再発胃がんに対するオプジーボと化学療法の併用効果を評価します。全国約30の医療機関が参加し、データ入力の効率化、データの正確性の向上、解析の迅速化を目指しています。

目次

第1章 エグゼクティブ概要

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界の市場規模と成長

• 世界のがん免疫療法創薬アウトソーシング市場：促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界のがん免疫療法創薬アウトソーシング市場の実績：規模と成長、2018～2023年
• 世界のがん免疫療法創薬アウトソーシング市場の予測：規模と成長、2023～2028年、2033年

第6章 市場セグメンテーション

• 世界のがん免疫療法創薬アウトソーシング市場：薬剤タイプ別、実績と予測、2018～2023年、2023～2028年、2033年
• モノクローナル抗体
• 免疫調節薬
• 腫瘍溶解性ウイルス療法とがんワクチン
• その他
• 世界のがん免疫療法創薬アウトソーシング市場：サービスタイプ別、実績と予測、2018～2023年、2023～2028年、2033年
• 対象の識別と検証
• 鉛のスクリーニングと特性評価
• 細胞ベースのアッセイ
• 世界のがん免疫療法創薬アウトソーシング市場：治療領域別、実績と予測、2018～2023年、2023～2028年、2033年
• 肺がん
• 乳がん
• 悪性黒色腫
• その他の治療領域

第7章 地域別・国別分析

• 世界のがん免疫療法創薬アウトソーシング市場：地域別、実績と予測、2018～2023年、2023～2028年、2033年
• 世界のがん免疫療法創薬アウトソーシング市場：国別、実績と予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• がん免疫療法創薬アウトソーシング市場：競合情勢
• がん免疫療法創薬アウトソーシング市場：企業プロファイル
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Laboratory Corporation of America Holdings（LabCorp）
  • Eurofins Scientific SE
  • WuXi AppTec Co Ltd.

第31章 その他の大手企業と革新的企業

• Charles River Laboratories International Inc.
• PerkinElmer Inc
• Bio-Rad Laboratories Inc
• QIAGEN N.V.
• Evotec SE
• Shanghai ChemPartner Co. Ltd.
• Aragen Life Sciences Limited
• GenScript Biotech Corporation
• BGI Genomics Co. Ltd.
• NeoGenomics Laboratories Inc
• ARUP Laboratories
• Syngene International Limited
• BioDuro-Sundia
• Ambry Genetics Corporation
• Selvita

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の展望と潜在的な分析

第36章 付録

Cancer immunotherapy drug discovery outsourcing is a specialized service model within the pharmaceutical and biotech sectors. It involves entrusting aspects of cancer immunotherapy drug development to external service providers, typically contract research organizations (CROs) or contract development and manufacturing organizations (CDMOs). This approach accelerates innovation by leveraging external expertise and resources, allowing pharmaceutical companies to concentrate on their core activities.

The primary drug types involved in cancer immunotherapy drug discovery outsourcing include monoclonal antibodies, immunomodulators, oncolytic viral therapies, cancer vaccines, and others. Monoclonal antibodies are laboratory-made molecules that mimic the immune system's ability to target specific proteins on cancer cells, aiding in fighting off harmful pathogens. The services provided encompass target identification and validation, lead screening and characterization, and cell-based assays utilized in therapeutic areas such as lung cancer, breast cancer, melanoma, and others.

The cancer immunotherapy drug discovery outsourcing market research report is one of a series of new reports from The Business Research Company that provides cancer immunotherapy drug discovery outsourcing market statistics, including cancer immunotherapy drug discovery outsourcing industry global market size, regional shares, competitors with a cancer immunotherapy drug discovery outsourcing market share, detailed cancer immunotherapy drug discovery outsourcing market segments, market trends and opportunities, and any further data you may need to thrive in the cancer immunotherapy drug discovery outsourcing industry. This cancer immunotherapy drug discovery outsourcing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cancer immunotherapy drug discovery outsourcing market size has grown rapidly in recent years. It will grow from $1.35 billion in 2023 to $1.5 billion in 2024 at a compound annual growth rate (CAGR) of 11.2%. The growth observed during the historic period can be attributed to several factors, including the rising incidence of adverse drug reactions, an increasing demand for comprehensive genomic testing, the global rise in cancer incidence, an expanding need for targeted therapy, and a growing number of clinical trials.

The cancer immunotherapy drug discovery outsourcing market size is expected to see rapid growth in the next few years. It will grow to $2.31 billion in 2028 at a compound annual growth rate (CAGR) of 11.4%. The anticipated growth in the forecast period can be attributed to several factors, including the growing significance of personalized medicine, the increasing availability of diagnostic tests, a heightened focus on personalized cancer therapy, rising healthcare expenditure, and the growing awareness of cancer incidence. Major trends expected in the forecast period encompass advancements in diagnostic technologies, the adoption of next-generation sequencing (NGS), the integration of artificial intelligence (AI), advancements in liquid biopsy technologies, the development of point-of-care companion diagnostic devices, and innovative testing technologies.

The escalating expenses associated with research and development (R&D) are projected to drive the expansion of the cancer immunotherapy drug discovery outsourcing market. The substantial R&D costs stem from the necessity of specialized expertise, costly equipment, and the inherent risks linked with innovation. The outsourcing of drug discovery activities taps into the economies of scale provided by contract research organizations (CROs), enabling smaller biotech firms and startups to optimize their R&D budgets and allocate resources more efficiently, thereby enhancing cost-effectiveness. For instance, in June 2023, as reported by the European Federation of Pharmaceutical Industries and Associations (EFPIA), the total pharmaceutical R&D expenditure in Europe reached $49,500 million (€44,500 million) in 2022, marking a rise of around 6.45% from $46,500 million (€42,533 million) in 2021. Consequently, the exorbitant costs associated with in-house research and development are fueling the growth of the cancer immunotherapy drug discovery outsourcing market.

Key players in the cancer immunotherapy drug discovery outsourcing market are embracing a strategic partnership approach to bolster cancer drug production and gain competitive advantages. Strategic partnerships typically involve collaborative relationships among two or more organizations, pooling their resources, expertise, and efforts to achieve common goals or objectives. For instance, in February 2022, Ono Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company, and Bristol-Myers Squibb, a US-based biopharmaceutical company, forged an outsourcing agreement with Prime Research Institute for Medical Research, Inc., a Japan-based research institute, for a joint clinical research project focused on gastric cancer patients treated with Opdivo (nivolumab) in combination with chemotherapy. This collaborative initiative, sponsored by the industry, encompasses a large-scale, multi-institutional study employing PRiME-R's CyberOncology data input support system, facilitating the standardization, structuring, management, and integration of real-world data in routine cancer clinical practice. The clinical research, utilizing CyberOncology, assesses the effectiveness of Opdivo combined with chemotherapy for untreated advanced or recurrent gastric cancer. Involving approximately 30 medical institutions nationwide, the study aims to streamline data input, improve data accuracy, and expedite analysis.

In February 2021, Charles River Laboratories, a US-based pharmaceutical company specializing in drug delivery products and services, acquired Cognate BioServices for $875 million. This acquisition positions Charles River to enhance its capabilities in cell and gene therapy development, testing, and manufacturing, while also complementing its existing range of non-clinical services, thereby offering clients comprehensive solutions spanning from initial research and discovery to CGMP production. Cognate BioServices, based in the US, is a contract manufacturing company specializing in the production of cellular immunotherapy and immune-oncology products.

Major companies operating in the cancer immunotherapy drug discovery outsourcing market are Thermo Fisher Scientific Inc., Danaher Corporation, Laboratory Corporation of America Holdings (LabCorp), Eurofins Scientific SE, WuXi AppTec Co Ltd., Charles River Laboratories International Inc., PerkinElmer Inc, Bio-Rad Laboratories Inc, QIAGEN N.V., Evotec SE, Shanghai ChemPartner Co. Ltd., Aragen Life Sciences Limited, GenScript Biotech Corporation, BGI Genomics Co. Ltd., NeoGenomics Laboratories Inc, ARUP Laboratories, Syngene International Limited, BioDuro-Sundia, Ambry Genetics Corporation, Selvita, Crown Bioscience International, CENTOGENE N.V., Jubilant Biosys, Oncodesign Services, Icagen Inc., Reaction Biology Corporation, ChemBridge Corporation

North America was the largest region in the cancer immunotherapy drug discovery outsourcing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy drug discovery outsourcing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cancer immunotherapy drug discovery outsourcing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cancer immunotherapy drug discovery outsourcing market includes revenues earned by entities by providing services such as preclinical testing, clinical trial support, and biomarker discovery. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cancer Immunotherapy Drug Discovery Outsourcing Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cancer immunotherapy drug discovery outsourcing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cancer immunotherapy drug discovery outsourcing? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cancer immunotherapy drug discovery outsourcing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Monoclonal Antibodies; Immunomodulators; Oncolytic Viral Therapies And Cancer Vaccines; Other Drug Types
• 2) By Service Type: Target Identification And Validation; Lead Screening And Characterization; Cell-based Assays
• 3) By Therapeutic Area: Lung Cancer; Breast Cancer; Melanoma; Other Therapeutic Areas
• Companies Mentioned: Thermo Fisher Scientific Inc.; Danaher Corporation; Laboratory Corporation of America Holdings (LabCorp); Eurofins Scientific SE; WuXi AppTec Co Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cancer Immunotherapy Drug Discovery Outsourcing Market Characteristics

3. Cancer Immunotherapy Drug Discovery Outsourcing Market Trends And Strategies

4. Cancer Immunotherapy Drug Discovery Outsourcing Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Cancer Immunotherapy Drug Discovery Outsourcing Market Size and Growth

• 5.1. Global Cancer Immunotherapy Drug Discovery Outsourcing Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Cancer Immunotherapy Drug Discovery Outsourcing Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Cancer Immunotherapy Drug Discovery Outsourcing Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Cancer Immunotherapy Drug Discovery Outsourcing Market Segmentation

• 6.1. Global Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Monoclonal Antibodies
• Immunomodulators
• Oncolytic Viral Therapies And Cancer Vaccines
• Other Drug Types
• 6.2. Global Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Target Identification And Validation
• Lead Screening And Characterization
• Cell-based Assays
• 6.3. Global Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Lung Cancer
• Breast Cancer
• Melanoma
• Other Therapeutic Areas

7. Cancer Immunotherapy Drug Discovery Outsourcing Market Regional And Country Analysis

• 7.1. Global Cancer Immunotherapy Drug Discovery Outsourcing Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Cancer Immunotherapy Drug Discovery Outsourcing Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Cancer Immunotherapy Drug Discovery Outsourcing Market

• 8.1. Asia-Pacific Cancer Immunotherapy Drug Discovery Outsourcing Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Cancer Immunotherapy Drug Discovery Outsourcing Market

• 9.1. China Cancer Immunotherapy Drug Discovery Outsourcing Market Overview
• 9.2. China Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Cancer Immunotherapy Drug Discovery Outsourcing Market

• 10.1. India Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Cancer Immunotherapy Drug Discovery Outsourcing Market

• 11.1. Japan Cancer Immunotherapy Drug Discovery Outsourcing Market Overview
• 11.2. Japan Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Cancer Immunotherapy Drug Discovery Outsourcing Market

• 12.1. Australia Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Cancer Immunotherapy Drug Discovery Outsourcing Market

• 13.1. Indonesia Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Cancer Immunotherapy Drug Discovery Outsourcing Market

• 14.1. South Korea Cancer Immunotherapy Drug Discovery Outsourcing Market Overview
• 14.2. South Korea Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Cancer Immunotherapy Drug Discovery Outsourcing Market

• 15.1. Western Europe Cancer Immunotherapy Drug Discovery Outsourcing Market Overview
• 15.2. Western Europe Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Cancer Immunotherapy Drug Discovery Outsourcing Market

• 16.1. UK Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Cancer Immunotherapy Drug Discovery Outsourcing Market

• 17.1. Germany Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Cancer Immunotherapy Drug Discovery Outsourcing Market

• 18.1. France Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Cancer Immunotherapy Drug Discovery Outsourcing Market

• 19.1. Italy Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Cancer Immunotherapy Drug Discovery Outsourcing Market

• 20.1. Spain Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Cancer Immunotherapy Drug Discovery Outsourcing Market

• 21.1. Eastern Europe Cancer Immunotherapy Drug Discovery Outsourcing Market Overview
• 21.2. Eastern Europe Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Cancer Immunotherapy Drug Discovery Outsourcing Market

• 22.1. Russia Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Cancer Immunotherapy Drug Discovery Outsourcing Market

• 23.1. North America Cancer Immunotherapy Drug Discovery Outsourcing Market Overview
• 23.2. North America Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Cancer Immunotherapy Drug Discovery Outsourcing Market

• 24.1. USA Cancer Immunotherapy Drug Discovery Outsourcing Market Overview
• 24.2. USA Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Cancer Immunotherapy Drug Discovery Outsourcing Market

• 25.1. Canada Cancer Immunotherapy Drug Discovery Outsourcing Market Overview
• 25.2. Canada Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Cancer Immunotherapy Drug Discovery Outsourcing Market

• 26.1. South America Cancer Immunotherapy Drug Discovery Outsourcing Market Overview
• 26.2. South America Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Cancer Immunotherapy Drug Discovery Outsourcing Market

• 27.1. Brazil Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Cancer Immunotherapy Drug Discovery Outsourcing Market

• 28.1. Middle East Cancer Immunotherapy Drug Discovery Outsourcing Market Overview
• 28.2. Middle East Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Cancer Immunotherapy Drug Discovery Outsourcing Market

• 29.1. Africa Cancer Immunotherapy Drug Discovery Outsourcing Market Overview
• 29.2. Africa Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Service Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Cancer Immunotherapy Drug Discovery Outsourcing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Cancer Immunotherapy Drug Discovery Outsourcing Market Competitive Landscape And Company Profiles

• 30.1. Cancer Immunotherapy Drug Discovery Outsourcing Market Competitive Landscape
• 30.2. Cancer Immunotherapy Drug Discovery Outsourcing Market Company Profiles
  • 30.2.1. Thermo Fisher Scientific Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Danaher Corporation
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Laboratory Corporation of America Holdings (LabCorp)
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Eurofins Scientific SE
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. WuXi AppTec Co Ltd.
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Cancer Immunotherapy Drug Discovery Outsourcing Market Other Major And Innovative Companies

• 31.1. Charles River Laboratories International Inc.
• 31.2. PerkinElmer Inc
• 31.3. Bio-Rad Laboratories Inc
• 31.4. QIAGEN N.V.
• 31.5. Evotec SE
• 31.6. Shanghai ChemPartner Co. Ltd.
• 31.7. Aragen Life Sciences Limited
• 31.8. GenScript Biotech Corporation
• 31.9. BGI Genomics Co. Ltd.
• 31.10. NeoGenomics Laboratories Inc
• 31.11. ARUP Laboratories
• 31.12. Syngene International Limited
• 31.13. BioDuro-Sundia
• 31.14. Ambry Genetics Corporation
• 31.15. Selvita

32. Global Cancer Immunotherapy Drug Discovery Outsourcing Market Competitive Benchmarking

33. Global Cancer Immunotherapy Drug Discovery Outsourcing Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Cancer Immunotherapy Drug Discovery Outsourcing Market

35. Cancer Immunotherapy Drug Discovery Outsourcing Market Future Outlook and Potential Analysis

• 35.1 Cancer Immunotherapy Drug Discovery Outsourcing Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Cancer Immunotherapy Drug Discovery Outsourcing Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Cancer Immunotherapy Drug Discovery Outsourcing Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer